MKMasato Katagiri

Masato Katagiri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masato Katagiri has a total of 116 co-authors. Here are the top co-authors by number of shared publications:

  • Masanori Yokoba

    School of Allied Health Sciences, Kitasato University, Sagamihara-city, Kanagawa 252-0373, Japan

    12 shared publications
  • Hisashi Mitsufuji

    Kitasato University School of Nursing, Sagamihara-City, Kanagawa 252-0329, Japan

    8 shared publications
  • Satoshi Igawa

    Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Japan

    8 shared publications
  • Akira Takakura

    Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara 252-0374, Kanagawa, Japan,

    6 shared publications
  • Jiichiro Sasaki

    Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara-City, Kanagawa 252-0374, Japan

    6 shared publications
  • Noriyuki Masuda

    Kitasato University School of Medicine

    6 shared publications

Latest Publications

  • Sniff and reverse-sniff nasal respiratory pressures after exacerbation of chronic obstructive pulmonary disease: A single-center prospective study

    by Tsuyoshi Ichikawa, Sakurako Tajiri, Masanori Yokoba, Yu Horimizu, Saki Yamaguchi, Akiko Kawakami, Masahiko Kimura, Tetsuri Kondo, Masato Katagiri, Minoru Toyokura

  • Open Access

    Panton-Valentine Leukocidin Induces Cytokine Release and Cytotoxicity Mediated by the C5a Receptor on Rabbit Alveolar Macrophages

    by Shinya Harada, Hayato Kawada, Shotaro Maehana, Hidehito Matsui, Makoto Kubo, Fumiaki Kojima, Hidero Kitasato, Masato Katagiri

    Necrotizing pneumonia caused by Panton-Valentine leukocidin (PVL)-positive community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) has high mortality, and is currently a serious clinical issue. PVL is a two-component toxin consisting of LukS-PV and LukF-PV. PVL was shown to cause necrosis in target cells by forming pores consisting of an octamer comprised of LukS-PV and LukF-PV. However, because of the specificity of PVL toward several target cells and species, the detailed action of PVL remains controversial. Therefore, we focused on necrotizing pneumonia caused by PVL-positive Staphylococcus aureus and clarified the effects of PVL on alveolar macrophages, which play a central role in innate immunity in the alveolar space. We constructed recombinant PVL (rPVL) components and stimulated alveolar macrophages isolated from rabbits, and then evaluated the cytotoxicity and pro-inflammatory cytokine release. Recombinant LukS-PV (rLukS-PV), but not recombinant LukF-PV (rLukF-PV), induced pro-inflammatory cytokine release. Especially, TNF-α release was mediated via the C5a receptor (C5aR) expressed in rabbit alveolar macrophages and rPVL, consisting of rLukS-PV and rLukF-PV, was highly toxic to rabbit alveolar macrophages via the same receptor. Our results, which reveal the action of PVL via C5aR on alveolar macrophages, may be useful for understanding the mechanism of necrotizing pneumonia caused by PVL.


  • Open Access

    Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer

    by Satoshi Igawa, Taihei Ono, Masashi Kasajima, Hideaki Manabe, Tomoya Fukui, Hisashi Mitsufuji, Masanori Yokoba, Masaru Kubota, Masato Katagiri, Jiichiro Sasaki, et al.

    Purpose: Amrubicin (AMR) is an anticancer drug for patients with relapsed small-cell lung cancer (SCLC). However, the efficacy of AMR in elderly patients with relapsed SCLC after chemotherapy by carboplatin plus etoposide (CE) has not been sufficiently evaluated. Patients and Methods: The medical records of patients with relapsed SCLC who received AMR as second-line chemotherapy were retrospectively reviewed, and their treatment outcomes were evaluated. Results: Forty-one patients with a median age of 76 years were analyzed. The overall response rate was 26.8%. Median progression-free survival (PFS) and overall survival (OS) were 3.5 and 8.1 months, respectively. While the median PFS of 4.7 and 2.8 months in the sensitive relapse and the refractory relapse group differed significantly (P=0.043), respectively, the median OS of 10.7 and 6.8 months in the respective relapse groups did not indicate a statistically significant difference (P=0.24). The median PFS in a group with a modified Glasgow prognostic score (mGPS) of 0 and a group with a mGPS 1 or 2 were 4.5 and 1.6 months (P=0.052), respectively, and the median OS in the respective mGPS groups were 10.7 and 4.4 months (P=0.034). Multivariate analysis identified good performance status, limited disease, and mGPS 0 as favorable independent predictors of PFS and OS of AMR monotherapy. Grade 3 or higher neutropenia was observed in 23 patients (56%), and febrile neutropenia was observed in nine patients (22%). Non-hematological toxic effects were relatively mild, and pneumonitis and treatment-related deaths were not observed. Conclusion: AMR is an effective and feasible regimen for elderly patients with relapsed SCLC after CE therapy.


  • Open Access

    Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study

    by Satoshi Igawa, Taihei Ono, Masashi Kasajima, Mikiko Ishihara, Yasuhiro Hiyoshi, Seiichiro Kusuhara, Noriko Nishinarita, Tomoya Fukui, Masaru Kubota, Jiichiro Sasaki, et al.

    Purpose: A T790M of the epidermal growth factor receptor (EGFR) is the most frequently encountered mutation conferring acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). The aim of this study was to assess the differential clinical outcomes of osimertinib therapy in NSCLC patients with T790M according to the type of activating EGFR mutation, ie, exon 19 deletion or L858R point mutation. Patients and methods: A prospective observational cohort study was conducted to evaluate the efficacy and safety of osimertinib in patients with a major EGFR mutation and T790M-positive advanced NSCLC who had disease progression after first-line EGFR-TKI therapy. The efficacy of osimertinib was evaluated according to the type of EGFR mutation. Results: A total of 51 patients were included in this study. An objective response was obtained in 29 patients, indicating an objective response rate of 58.8%. The response rate was 69.7% in patients with exon 19 deletion and 38.9% in patients with L858R point mutation, indicating a statistically significant difference (P=0.033). The median progression-free survival (PFS) and overall survival (OS) of the entire patient population were 7.8 and 15.5 months, respectively. The median PFS in the exon 19 deletion and L858R point mutation groups was 8.0 months and 5.2 months, respectively, indicating a statistically significant difference (P=0.045). Median OS in the exon 19 deletion and L858R point mutation groups was significantly different at 19.8 months and 12.9 months, respectively (P=0.0015). Multivariate analysis identified the exon 19 deletion as a favorable independent predictor of PFS and OS. Conclusion: Investigators should consider the proportions of sensitive EGFR mutation types as a stratification factor in designing or reviewing clinical studies involving osimertinib.


  • Open Access

    Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease

    by Satoshi Igawa, Noriko Nishinarita, Akira Takakura, Takahiro Ozawa, Shinya Harada, Seiichiro Kusuhara, Hideyuki Niwa, Shinji Hosotani, Hideyuki Sone, Yoshiro Nakahara, et al.

    Background: The optimal chemotherapy regimen for non-small-cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) remains unknown. Therefore, in this study, we investigated the real-world efficacy and safety of carboplatin (CBDCA) plus nab-paclitaxel (nab-PTX) as a first-line regimen for NSCLC patients with ILD. Patients and methods: We retrospectively reviewed advanced NSCLC patients with ILD who had received CBDCA plus nab-PTX as a first-line chemotherapy regimen between April 2013 and March 2018. Patients were diagnosed with ILD based on the findings of a pretreatment high-resolution computed tomography of the chest. Results: The 34 patients enrolled in this study were included in the efficacy and safety analysis. Collagen vascular disease or a history of exposure to dust or asbestos was not reported for any patients. The median age of patients was 71 years (range, 59–83 years), and 32 patients had a performance status of 0 or 1. The overall response rate was 38.2%. The median progression-free survival and overall survival were 5.8 months and 12.7 months, respectively. Chemotherapy-related acute exacerbation of ILD was observed in two patients (5.7%). Other toxicities were feasible, and no treatment-related deaths occurred. Conclusion: CBDCA plus nab-PTX, as a first-line chemotherapy regimen for NSCLC, showed favorable efficacy and safety in patients with preexisting ILD.


  • Open Access

    Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer

    by Masayuki Shirasawa, Tomoya Fukui, Seiichiro Kusuhara, Yasuhiro Hiyoshi, Mikiko Ishihara, Masashi Kasajima, Yoshiro Nakahara, Sakiko Otani, Satoshi Igawa, Masanori Yokoba, et al.

    Background: Small cell lung cancer (SCLC) is typically categorized according to disease extent as limited or extensive, and utility of the 8th TNM classification, recommended for lung cancer staging, which demonstrates a strong association with non-small-cell lung cancer (NSCLC) management, remains unclear. Methods: This retrospective study included 277 consecutive SCLC patients treated at a single institution between 2008 and 2016. Results: According to the currently used two-stage system, 186 (65.7%) of the patients were classified as having extensive disease (ED)-SCLC. Among the ED-SCLC patients, ten (5.3%), 38 (20.4%), 32 (17.2%), and 106 (57.0%) were categorized into stages M0, M1a, M1b, and M1c, respectively, according to the 8th TNM classification. There was a significant difference in overall survival based on the M descriptors: 15.8 (95% CI 9.4–22.2) months in the M1b group vs 7.3 (95% CI 5.7–8.9) months in the M1c group (PPConclusion: The 8th TNM classification has a prognostic value in SCLC. Similarly to NSCLC, treatment approaches should be considered on the basis of the 8th TNM classification, especially stage IVA separate from stage IVB in ED-SCLC patients.


  • Genioglossus muscle activity during sniff and reverse sniff in healthy men

    by Tsuyoshi Ichikawa, Masanori Yokoba, Masahiko Kimura, Manaka Shibuya, Paul A. Easton, Masato Katagiri

    New Findings: What is the central question of this study? Maximal sniff nasal inspiratory and reverse sniff nasal expiratory pressures are measured as inspiratory and expiratory muscle strength, respectively. Is the genioglossus muscle activated during short maximal inspiratory and expiratory efforts through the nose? What is the main finding and its importance? Genioglossus muscle activity occurred with inspiratory muscle activity during a maximal sniff and with expiratory muscle activity during a maximal reverse sniff. These results indicate that genioglossus muscle activity is closely related to the generation of maximal sniff nasal inspiratory and reverse sniff nasal expiratory pressures. Maximal sniff nasal inspiratory pressure (SNIPmax) is widely used to assess inspiratory muscle strength. The sniff nasal inspiratory pressure (SNIP) is lower in patients with neuromuscular disease with bulbar involvement compared with those without, possibly owing to impaired upper airway muscle function. However, the degree to which the genioglossus (GG) muscle, one of the upper airway muscles, is activated during inspiratory and expiratory efforts through the nose remains unclear. Therefore, we examined GG activity during short and sharp inspiratory and expiratory efforts through the nose, i.e. sniff and reverse sniff manoeuvres. In eight normal young subjects, we inserted fine wire electrodes into the GG muscle, parasternal intercostal and scalene (inspiratory) muscles and transversus abdominis (expiratory) muscle. We assessed EMG activity of each muscle and measured SNIP and reverse sniff nasal expiratory pressure (RSNEP) during sniffs and reverse sniffs from low to high intensities in the sitting position. The highest SNIP and RSNEP were analysed as SNIPmax and maximal RSNEP (RSNEPmax), respectively. In each subject, GG EMG activity increased linearly with increasing SNIP and RSNEP. The SNIPmax and RSNEPmax were −85.1 ± 15.9 and 83.2 ± 24.2 cmH2O, respectively. Genioglossus EMG activity varied with EMG activity of the parasternal intercostal and scalene muscles during generation of SNIPmax and with EMG activity of the transversus abdominis muscle during RSNEPmax. Genioglossus EMG activity during generation of SNIPmax was higher than during RSNEPmax (62.9 ± 31.1% EMG of SNIPmax, P = 0.012). These results suggested that GG activity was closely related to the generation of both SNIPmax and RSNEPmax.


  • MP503OXIDATIVE STRESS INCREASES MEGALIN EXPRESSION THROUGH PI3K/AKT SIGNALING IN RENAL PROXIMAL TUBULAR CELLS

    by Yoshifumi Kurosaki, Akemi Imoto, Masanori Yokoba, Tsuneo Takenaka, Masato Katagiri, Takafumi Ichikawa, Naohito Ishii

    INTRODUCTION AND AIMS: Megalin, an endocytic receptor in proximal tubular cells, plays a critical role in renal tubular protein reabsorption. Megalin is involved in albuminuria in diabetic nephropathy. We previously showed that renal megalin expression increased in type 1 diabetes mellitus in normoalbuminuric stage. However, mechanisms underlying megalin expression in type 1 diabetes mellitus remain unclear. In the present study, we evaluated whether oxidative stress affected megalin expression in HK-2 cells, which are immortalized human proximal tubular cells.

  • Co-expression of S100A14 and S100A16 is a predictive marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinomas

    by Ken Katono, Yuichi Sato, Shinichiro Ryuge, Ryo Nagashio, Masanori Yokoba, Masato Katagiri, Kazu Shiomi, Yukitoshi Satoh, Noriyuki Masuda

    Background: Although, adjuvant cisplatin-based chemotherapy improves survival in resected non-small cell lung cancer, some patients have no survival benefit. S100A14 and S100A16 is thought to play key roles during different steps of tumor progression. The aims of this study was to investigate prognostic value of S100A14 and S100A16 expression for platinum-based adjuvant chemotherapy in resected lung adenocarcinomas. Methods: S100A14 and S100A16 expression was immunohistochemically studied in 65 consecutive patients of lung adenocarcinomas who underwent complete resection and received adjuvant platinum-based chemotherapy. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate the effect of S100A14 and S100A16 expression on disease-free survival (DFS) and overall survival (OS). Results: S100A14 expression was not correlated with DFS or OS. S100A16 expression was significantly correlated with OS (P = 0.009). Co-expression of S100A14 and S100A16 was significantly correlated with DFS (P =0.031) and OS (P =0.015). In multivariable analysis, S100A16 expression independently predicted a poorer survival (HR, 3.38; 95%CI, 1.52-7.49; P = 0.003). Co-expression of S100A14 and S100A16 expression independently predicted a higher recurrence (HR, 1.89; 95%CI, 1.03-3.46; P = 0.04), and a poorer survival (HR, 3.10; 95%CI, 1.41-6.81; P = 0.005). Conclusions: The present study revealed that co-expression of S100A14 and S100A16 expression is predictive marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinomas. Further large scale study is needed to confirm present results.